Conquering Diseases

Study Of An Investigational Drug To Reduce Virus And Prevent Inflammation In Hospitalized Covid-19 Adults

Description

Seeking men and women who have been hospitalized for COVID-19 and are within one week of first experiencing COVID-19 symptoms for a study of an investigational drug to reduce the virus and prevent inflammation.

Overview

Participants in this study will be randomly assigned to get either the investigational drug or placebo (looks like the drug, but contains no medicine). All participants will receive standard care such as dexamethasone, convalescent plasma and/or remdesivir, After being discharged from the hospital participants would have a maximum of 2 in-person follow-up visits and 1 telephone visit.

What we're hoping for

We are comparing a investigational drug compared to placebo to improve lung function by reducing virus and preventing inflammation when added to standard of care therapy for hospitalized COVID-19 patients.

Additional Information

ClinicalTrials.gov Identifier: NCT04439071

 Principal Investigator

Robert  Finberg, MD

University of Massachusetts Medical School

 Study Contact

Shestruma  Parajuli

shestruma.parajuli@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989